News 3/16

top of page

AbbVie and Simcere Zaiming Collaborate to Develop Innovative Treatment for Multiple Myeloma | iPharmaCenter

ipharmaservices

Jan 21

FDA Approves Omvoh for Crohn’s Disease, Expanding Its Reach in Inflammatory Bowel Disease Treatment | iPharmaCenter

ipharmaservices

Jan 21

Johnson & Johnson Expands Neuroscience Portfolio with Acquisition of Intra-Cellular Therapies | iPharmaCenter

Johnson & Johnson Expands Neuroscience Portfolio with Acquisition of Intra-Cellular Therapies | iPharmaCenter

Johnson & Johnson Expands Neuroscience Portfolio with Acquisition of Intra-Cellular Therapies | iPharmaCenter

ipharmaservices

Jan 21

J.P. Morgan Healthcare Conference 2025 | Novartis | Merck | News | Updates

ipharmaservices

Jan 18

Sanofi Reports Positive Results for Subcutaneous Sarclisa, Aiming to Strengthen Competition with Darzalex | iPharmaCenter

ipharmaservices

Jan 9

Top selling cancer drugs of 2024 | Best selling cancer drugs | Top cancer drugs by revenues in 2024 | iPharmaCenter

Top selling cancer drugs of 2024 | Best selling cancer drugs | Top cancer drugs by revenues in 2024 | iPharmaCenter

Top selling cancer drugs of 2024 | Best selling cancer drugs | Top cancer drugs by revenues in 2024 | iPharmaCenter

ipharmaservices

Jan 9

Valo Health and Novo Nordisk Expand Partnership to Develop Treatments for Cardiometabolic Diseases | iPharmaCenter

ipharmaservices

Jan 8

Novartis aims to treat broader patient population with intrathecal onasemnogene abeparvovec | iPharmaCenter

ipharmaservices

Jan 2

Expected best selling drugs of 2025 | Top pharmaceuticals by revenues | iPharmaCenter

Expected best selling drugs of 2025 | Top pharmaceuticals by revenues | iPharmaCenter

Expected best selling drugs of 2025 | Top pharmaceuticals by revenues | iPharmaCenter

ipharmaservices

Jan 1

Bristol Myers Squibb Reports Positive Results from Phase 3 Trials of Deucravacitinib in Psoriatic Arthritis | iPharmaCenter

ipharmaservices

Dec 27, 2024

After Tavapadon Success in Phase 3 Prakinson's Disease Trial, Emraclidine Fails In Schizophrenia | Shares Tumbles by 12% | iPharmaCenter

ipharmaservices

Nov 12, 2024

Alexion's Koselugo Shows Improved Objective Response Rate in Adults with Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas

ipharmaservices

Nov 12, 2024

Best selling immunology drugs by revenues | Top immunology drugs | 2024 | iPharmaCenter

Best selling immunology drugs by revenues | Top immunology drugs | 2024 | iPharmaCenter

Best selling immunology drugs by revenues | Top immunology drugs | 2024 | iPharmaCenter

ipharmaservices

Aug 30, 2024

Expected | Best selling drugs of 2024 | Top selling drugs of 2024 | iPharmaCenter

Expected | Best selling drugs of 2024 | Top selling drugs of 2024 | iPharmaCenter

Expected | Best selling drugs of 2024 | Top selling drugs of 2024 | iPharmaCenter

ipharmaservices

Jul 21, 2024

LEQEMBI (Lecanemab) Receives Approval in Israel for Treating Alzheimer's Disease | iPharmaCenter

ipharmaservices

Jul 15, 2024

Pharmaceutical deals | Acquistions | 2024 | iPharmaCenter

Pharmaceutical deals | Acquistions | 2024 | iPharmaCenter

Pharmaceutical deals | Acquistions | 2024 | iPharmaCenter

ipharmaservices

Jul 8, 2024

Lilly's Tirzepatide Shows Promise in MASH Treatment, Achieves Notable Results in Phase 2 Study | iPharmaCenter

ipharmaservices

Jun 9, 2024

European Commission Approves Opdivo with Cisplatin and Gemcitabine for First-Line Treatment of Advanced Urothelial Carcinoma | iPharmaCenter

European Commission Approves Opdivo with Cisplatin and Gemcitabine for First-Line Treatment of Advanced Urothelial Carcinoma | iPharmaCenter

European Commission Approves Opdivo with Cisplatin and Gemcitabine for First-Line Treatment of Advanced Urothelial Carcinoma | iPharmaCenter

ipharmaservices

May 30, 2024

Merck Announces Success in Phase 3 KEYNOTE-522 Trial for High-Risk Early-Stage Triple Negative Breast Cancer (TNBC) | iPharmaCenter

ipharmaservices

May 28, 2024

Australia Healthcare News | Media | Updates

ipharmaservices

May 13, 2024

bottom of page